Ranitidine Induced Hepatotoxicity: A Review
Open Access
- 20 May 2020
- journal article
- review article
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 8 (1), 39-46
- https://doi.org/10.15415/jptrm.2020.81006
Abstract
Background: Ranitidine (RAN) is one of the common drugs associated with idiosyncratic adverse drug reactions (IADRs) in humans. It was found to be associated with severe adverse drug reactions due to the presence of contaminants such as N-Nitrosodimethylamine (NDMA) which is claimed to be carcinogenic. As a consequence, on April 1, 2020, United States Food and Drug Administration (USFDA) had decided to call off all the RAN products from the market. The exact cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. Purpose: To summarize and analyze the reason behind the withdrawal of RAN products from the market and whether ranitidine will be available again in future or will FDA withdraw approvals of ranitidine National Drug Authority (NDA) and an abbreviated new drug application (ANDA)? Methods: We performed a systematic PubMed/MEDLINE search of studies investigating the reason behind the withdrawal of RAN products and explored the possible mechanism associated with RAN induced hepatotoxicity. Conclusion: RAN induced liver injury is difficult to diagnose and study because of its relative rarity and unpredictive occurrence. Recent studies suggest that most of the RAN associated idiosyncratic reactions may lead to hepatocyte damage, followed by a series of events, such as activation of specific T- and B-cells, release of proinflammatory mediators like TNFα, interleukins, various cytokines and chemokines. The exact cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. More studies must be carried out on this to know about the exact reason behind RAN associated hepatotoxicity.Keywords
This publication has 26 references indexed in Scilit:
- Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United StatesChemical Research in Toxicology, 2011
- Market withdrawal of new molecular entities approved in the United States from 1980 to 2009Pharmacoepidemiology and Drug Safety, 2011
- Risk Factors for Idiosyncratic Drug-Induced Liver InjuryGastroenterology, 2010
- Drug-Induced Liver Injury: Review ArticleDigestive Diseases and Sciences, 2007
- Mechanisms of drug-induced liver injuryThe AAPS Journal, 2006
- Unique Gene Expression and Hepatocellular Injury in the Lipopolysaccharide-Ranitidine Drug Idiosyncrasy Rat Model: Comparison with FamotidineToxicological Sciences, 2006
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005
- Switching of Prescription Drugs to Over-the-Counter StatusDrugs & Aging, 2005
- Idiosyncratic Liver Injury: Challenges and ApproachesToxicologic Pathology, 2005
- RanitidineThe New England Journal of Medicine, 1984